Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Insights - The approval of Lurcatinib cream marks a significant opportunity in the vitiligo market, being the first and only targeted therapy approved in China for this condition [7] - Clinical trials have shown positive results, with a significant percentage of patients achieving at least a 75% improvement in facial vitiligo area score after 24 weeks of treatment [7] - The company is also pursuing additional indications for Lurcatinib cream, including atopic dermatitis, which could further enhance its market potential [7] Financial Forecast and Valuation - Revenue projections for the company are as follows: 2023: 8,013 million RMB, 2024: 7,469 million RMB, 2025: 8,166 million RMB, 2026: 9,628 million RMB, and 2027: 12,069 million RMB, with growth rates of -12.4%, -6.8%, 9.3%, 17.9%, and 25.4% respectively [6] - Net profit forecasts are: 2023: 2,401 million RMB, 2024: 1,620 million RMB, 2025: 1,681 million RMB, 2026: 1,942 million RMB, and 2027: 2,333 million RMB, with growth rates of -26.3%, -32.5%, 3.8%, 15.6%, and 20.1% respectively [6] - The estimated reasonable market value for the company in 2026 is 677 billion HKD, based on a combination of price-to-earnings and price-to-sales ratios [7]

Investment Rating - The report maintains a "Buy" rating for Geely Automobile (0175.HK) [5] Core Views - The company is experiencing growth driven by both plug-in hybrid and export sales, with Zeekr leading the growth [9] - The report highlights a differentiated development in the new energy sector, with plug-in hybrid vehicles showing a 37% year-on-year increase, while pure electric vehicle sales declined by 15% [9] - The export market has seen a significant increase of 121% year-on-year, indicating a successful transition from simple product exports to localized operations [9] - The establishment of a joint venture for core technology research and testing services is expected to enhance long-term competitiveness [9] Financial Forecasts and Indicators - Revenue projections for 2024, 2025, 2026, and 2027 are estimated at 240,194 million, 404,783 million, 489,688 million, and 572,828 million RMB respectively, with growth rates of 34.0%, 68.5%, 21.0%, and 17.0% [4] - Net profit forecasts for the same years are 16,632 million, 16,208 million, 22,085 million, and 25,971 million RMB, with growth rates of 213.3%, -2.6%, 36.3%, and 17.6% [4] - Earnings per share (EPS) are projected to be 1.53, 1.49, 2.03, and 2.38 RMB for 2024, 2025, 2026, and 2027 respectively [4] - The price-to-earnings (P/E) ratio is expected to be 10, 10, 7, and 6 for the respective years [4] - The price-to-book (P/B) ratio is projected at 1.8, 1.6, 1.3, and 1.1 [4]

Investment Rating - The report assigns a rating of "Buy" for the company [7]. Core Insights - The company's development business drag is gradually alleviating, and the value of commercial operations is becoming more prominent, with clear future growth space and direction [1]. - The report highlights the continuous revaluation of corporate value against the backdrop of REITs policy opening [1]. Financial Summary - Total revenue is projected to decline from 119,464 million RMB in 2023 to 40,927 million RMB in 2027, reflecting a decrease of 65.8% over the period [3]. - Net profit is expected to decrease from 879 million RMB in 2023 to 805 million RMB in 2027, with a significant increase of 213.3% in 2024 followed by fluctuations in subsequent years [3]. - The company's price-to-earnings (PE) ratio is forecasted to rise from 9.74 in 2023 to 18.25 in 2027, while the price-to-book (PB) ratio is expected to increase from 0.18 to 0.30 over the same period [3]. Market Data - The stock price has ranged between 1.69 and 2.71 HKD over the past 52 weeks, with a current market capitalization of 17,523 million HKD [4]. Business Strategy and Operations - The company has shifted its strategic focus from scale expansion to accelerating de-stocking and ensuring project delivery, confirming a bottom in profit margins [7]. - The commercial sector has been a significant support for the company during macroeconomic fluctuations, with stable cash flow contributions from rental income [7][30]. - The company has established a strong competitive advantage in the commercial sector, with a focus on deep operational capabilities and optimizing the competitive landscape [7]. Future Projections - The report forecasts earnings per share (EPS) of 0.07, 0.09, and 0.11 RMB for the years 2025, 2026, and 2027 respectively, with a projected net asset value per share of 6.72 RMB in 2026 [7]. - The company is expected to maintain a robust cash flow generation capability, with a significant increase in the interest coverage ratio from 0.87 in 2020 to 4.42 in the first half of 2025 [7][30].

Investment Rating - The report gives a "Buy" rating for the company, Softcare, for the first time [6]. Core Insights - Softcare is a multinational hygiene products company focused on emerging markets, particularly in Africa, Latin America, and Central Asia. It has established itself as a leader in the African baby diaper and sanitary napkin markets, holding market shares of 20.3% and 15.6% respectively as of 2024 [6][13]. - The company has experienced rapid revenue and profit growth due to the establishment of local production facilities in Africa, with projected revenues of $454 million in 2024, reflecting a year-on-year growth of 10.5% [5][17]. - The African market is expected to see significant growth in the hygiene products sector, driven by a young population, increasing urbanization, and rising disposable incomes [19][28]. Summary by Sections Company Overview - Softcare launched its first product, Softcare baby diapers, in Ghana in 2009 and has since expanded its brand portfolio to include Maya, Veesper, Cuettie, and Clincleer, catering to various consumer segments [10][13]. - The company has established eight production facilities across different African countries, enhancing its manufacturing capabilities and supply chain efficiency [10][41]. Market Potential - The African economy is projected to grow at a rate of 4.1% in 2025, which is higher than the global average, providing a favorable environment for the growth of hygiene products [19]. - The young population in Africa, with over 60% under the age of 30, and a birth rate of approximately 3.2% from 2020 to 2024, is expected to drive demand for baby products [23][24]. Competitive Advantages - Softcare has a well-defined brand matrix and has received multiple awards, enhancing its brand recognition and consumer trust [36][37]. - The company operates a robust distribution network with over 2,800 wholesalers, distributors, and retailers across Africa, Latin America, and Central Asia, ensuring extensive market reach [45][46]. - The local production strategy allows Softcare to reduce costs and improve product quality, with a significant increase in gross margins for its products from 2022 to 2024 [43][41]. Financial Projections - The company forecasts revenues of $534 million in 2025, with a compound annual growth rate (CAGR) of 17% from 2025 to 2027 [5][6]. - The projected net profit for 2024 is $95 million, with a significant increase in profitability expected in the coming years [5][17].

Investment Rating - The investment rating for the company is "Buy" (maintained) [2] Core Insights - The company announced the acquisition of a 29.06% stake in PUMA SE for €1.5 billion, becoming the largest shareholder, which is expected to enhance its global competitiveness and support its "single focus, multi-brand, globalization" strategy [2] - The company anticipates steady growth in 2026, with projected net profits of 12.977 billion, 14.560 billion, and 15.822 billion yuan for 2025, 2026, and 2027 respectively, reflecting a slight downward adjustment from previous estimates [2] - The company remains optimistic about its core categories and channel reforms, with potential growth driven by the upcoming Paris Olympics and strong performance from its FILA brand [2] Financial Summary and Valuation Metrics - Revenue projections for the company are as follows: 62.356 billion yuan in 2023, 70.826 billion yuan in 2024, 78.234 billion yuan in 2025, 85.959 billion yuan in 2026, and 94.151 billion yuan in 2027, with year-over-year growth rates of 16.2%, 13.6%, 10.5%, 9.9%, and 9.5% respectively [5] - Net profit estimates are 10.236 billion yuan for 2023, 15.596 billion yuan for 2024, 12.977 billion yuan for 2025, 14.560 billion yuan for 2026, and 15.822 billion yuan for 2027, with a notable decline of 16.8% in 2025 [5] - The company's EPS (Earnings Per Share) is projected to be 3.6 yuan in 2023, 5.5 yuan in 2024, 4.6 yuan in 2025, 5.2 yuan in 2026, and 5.7 yuan in 2027, with corresponding P/E ratios of 19.0, 13.1, 15.7, 13.4, and 12.3 [5]

Investment Rating - The report maintains a "Buy" rating for the company [1] Core Insights - The company has reported a significant increase in net profit for FY26H1, with an expected growth of 216%-231% year-on-year, and a growth of 315%-337% when excluding perpetual bond interest [6] - The integration of pulp and paper production has shown significant benefits, contributing to improved profitability [6] - The company is expected to increase its chemical pulp production capacity to 743 million tons by FY27, enhancing its cost advantages [6] - The industry supply-demand dynamics are improving, with some paper prices rebounding, which is expected to contribute positively to the company's profitability [6] Financial Data and Profit Forecast - Revenue projections for FY2024 to FY2028 are as follows: - FY2024: 59.496 billion RMB - FY2025: 63.241 billion RMB - FY2026E: 73.954 billion RMB - FY2027E: 80.367 billion RMB - FY2028E: 85.478 billion RMB - Net profit attributable to ordinary shareholders is projected to grow significantly, with estimates of 3.789 billion RMB for FY2026, 4.671 billion RMB for FY2027, and 5.702 billion RMB for FY2028 [5][7] - The company's earnings per share (EPS) is expected to reach 1.00 RMB for FY2026 and 1.22 RMB for FY2028 [5] Industry Context - The company operates in the light manufacturing sector, specifically in the paper industry, which is experiencing a recovery in demand and pricing [6] - The report highlights that the company has a significant production capacity exceeding 20 million tons, which provides substantial economies of scale [6]

Investment Rating - The report maintains an "Outperform" rating for the company [2][3] Core Views - The company is expected to see significant growth in its instant delivery segment, driven by increasing demand and strategic positioning within the market [3][4] - The company has reported a strong performance forecast for 2025, with net profit expected to be no less than RMB 238 million, representing an 80% increase from 2024 [3][4] - The report highlights the company's independent third-party platform as a key differentiator, enabling it to capture market opportunities and enhance customer relationships with major brands [3][4] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: RMB 12.4 billion - 2024: RMB 15.746 billion - 2025E: RMB 22.051 billion - 2026E: RMB 30.202 billion - 2027E: RMB 39.568 billion - Year-on-year revenue growth rates are projected at: - 2023: 20.80% - 2024: 26.98% - 2025E: 40.04% - 2026E: 36.96% - 2027E: 31.01% [3][7] - Net profit attributable to ordinary shareholders is forecasted as follows: - 2023: RMB 51 million - 2024: RMB 132 million - 2025E: RMB 238 million - 2026E: RMB 452 million - 2027E: RMB 755 million - Year-on-year net profit growth rates are projected at: - 2023: -117.63% - 2024: 161.81% - 2025E: 80.03% - 2026E: 89.46% - 2027E: 67.04% [3][7] - Earnings per share (EPS) is expected to increase from RMB 0.06 in 2023 to RMB 0.82 in 2027 [3][7] - The report notes a decrease in the price-to-earnings (PE) ratio from 48x in 2025E to 15x in 2027E, indicating a favorable valuation compared to peers [3][4]

Investment Rating - The report provides a positive outlook for CSPC Pharmaceutical Group, indicating a clear roadmap for internationalization and significant revenue growth expected from completed business development transactions by 2026 [5][6]. Core Insights - CSPC is projected to convert its completed business development transactions into recurring revenue by 2026, supported by major research milestones and successful overseas development progress [6]. - The company has secured approximately $10.2 billion in upfront and milestone payments from significant partnerships with AstraZeneca and Madrigal, which are expected to enhance profitability from 2025 to 2027 [5][6]. - Key products such as KN026 and SYS6010 are anticipated to drive domestic business recovery and accelerate growth post-2027 [7]. Summary by Sections Business Development and Revenue - CSPC's completed business development transactions are expected to yield around $9 billion in free cash flow from milestone payments by 2030, with AstraZeneca's recent $1.2 billion non-refundable upfront payment being a significant contributor [6]. - The company has established eight innovative R&D platforms, transitioning from a raw material producer to a complex generics and innovative drug enterprise, achieving a compound annual growth rate of 3.1% in profitability from 2019 to 2023 [10]. Market Position and Financials - As of February 2, 2026, CSPC's stock price was HKD 9.15, with a market capitalization of $13.54 billion [13]. - The company ranks among the top ten in the Chinese pharmaceutical industry by drug revenue, with a significant portion of its income derived from the Asian market [11]. Catalysts for Growth - Key catalysts include the progress of overseas R&D projects, particularly the core product EGFR ADC, and the clinical development plans of major partners like AstraZeneca [8]. - The anticipated launch of innovative drugs and the entry of early-stage products into clinical phases are expected to validate the company's R&D capabilities [8].

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has reported a significant increase in net profit for FY26H1, with an expected range of RMB 2.15-2.25 billion, representing a year-on-year growth of 216%-231%. After excluding perpetual bond interest of RMB 201 million, the attributable net profit is expected to be RMB 1.95-2.05 billion, reflecting a year-on-year increase of 315%-337% [8] - The integration of pulp and paper operations has shown significant effects, contributing to improved profitability. The company has a total of 5.43 million tons of pulp capacity, with plans to increase this to 7.43 million tons by FY27 [8] - The industry supply-demand dynamics are improving, with some paper prices rebounding, which is expected to contribute to profit elasticity [8] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - FY2024: RMB 59.496 billion (5% growth) - FY2025: RMB 63.241 billion (6% growth) - FY2026E: RMB 73.954 billion (17% growth) - FY2027E: RMB 80.367 billion (9% growth) - FY2028E: RMB 85.478 billion (6% growth) [7] - Attributable net profit forecasts are: - FY2024: RMB 751 million - FY2025: RMB 1.767 billion - FY2026E: RMB 3.789 billion - FY2027E: RMB 4.671 billion - FY2028E: RMB 5.702 billion [7] - The company’s earnings per share (EPS) are projected to be: - FY2024: RMB 0.16 - FY2025: RMB 0.38 - FY2026E: RMB 0.81 - FY2027E: RMB 1.00 - FY2028E: RMB 1.22 [7]

Investment Rating - The report maintains a rating of "Outperform" for the company [1] Core Insights - The company is expected to see significant growth in its revenue and net profit, with a projected revenue of RMB 22.05 billion in 2025, representing a year-on-year growth of 40.04% [2] - The demand for instant retail is rapidly increasing, and the company is well-positioned to capture this growth, especially with the strategic focus of major players like Alibaba on instant retail [5] - The company's independent third-party platform is a key differentiator, allowing it to serve a diverse range of clients and enhance its logistics capabilities [5] - The profit forecast has been adjusted downwards due to short-term impacts from new rider recruitment and share payments, but long-term growth prospects remain strong [5] Financial Data and Profit Forecast - Revenue projections for the company are as follows: - 2023: RMB 12.4 billion - 2024: RMB 15.746 billion - 2025E: RMB 22.051 billion - 2026E: RMB 30.202 billion - 2027E: RMB 39.568 billion - Net profit attributable to ordinary shareholders is expected to be: - 2023: RMB 51 million - 2024: RMB 132 million - 2025E: RMB 238 million - 2026E: RMB 452 million - 2027E: RMB 755 million - The company’s earnings per share (EPS) is projected to grow from RMB 0.06 in 2023 to RMB 0.82 in 2027 [2][6]